These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1139 related articles for article (PubMed ID: 11857337)
1. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337 [TBL] [Abstract][Full Text] [Related]
2. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. Bennett F; Luxenberg D; Ling V; Wang IM; Marquette K; Lowe D; Khan N; Veldman G; Jacobs KA; Valge-Archer VE; Collins M; Carreno BM J Immunol; 2003 Jan; 170(2):711-8. PubMed ID: 12517932 [TBL] [Abstract][Full Text] [Related]
3. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684 [TBL] [Abstract][Full Text] [Related]
4. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. Yamazaki T; Akiba H; Koyanagi A; Azuma M; Yagita H; Okumura K J Immunol; 2005 Aug; 175(3):1586-92. PubMed ID: 16034097 [TBL] [Abstract][Full Text] [Related]
5. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503 [TBL] [Abstract][Full Text] [Related]
7. Expression of programmed death 1 ligands by murine T cells and APC. Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930 [TBL] [Abstract][Full Text] [Related]
8. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells. Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772 [TBL] [Abstract][Full Text] [Related]
9. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. de Waal Malefyt R; Yssel H; de Vries JE J Immunol; 1993 Jun; 150(11):4754-65. PubMed ID: 7684412 [TBL] [Abstract][Full Text] [Related]
10. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. Kanai T; Totsuka T; Uraushihara K; Makita S; Nakamura T; Koganei K; Fukushima T; Akiba H; Yagita H; Okumura K; Machida U; Iwai H; Azuma M; Chen L; Watanabe M J Immunol; 2003 Oct; 171(8):4156-63. PubMed ID: 14530338 [TBL] [Abstract][Full Text] [Related]
12. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Habicht A; Kewalaramani R; Vu MD; Demirci G; Blazar BR; Sayegh MH; Li XC Am J Transplant; 2007 Dec; 7(12):2683-92. PubMed ID: 17924994 [TBL] [Abstract][Full Text] [Related]
14. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Latchman Y; Wood CR; Chernova T; Chaudhary D; Borde M; Chernova I; Iwai Y; Long AJ; Brown JA; Nunes R; Greenfield EA; Bourque K; Boussiotis VA; Carter LL; Carreno BM; Malenkovich N; Nishimura H; Okazaki T; Honjo T; Sharpe AH; Freeman GJ Nat Immunol; 2001 Mar; 2(3):261-8. PubMed ID: 11224527 [TBL] [Abstract][Full Text] [Related]
15. The poststimulation program of CD4 versus CD8 T cells (death versus activation-induced nonresponsiveness). Tham EL; Mescher MF J Immunol; 2002 Aug; 169(4):1822-8. PubMed ID: 12165505 [TBL] [Abstract][Full Text] [Related]
16. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Bu DX; Tarrio M; Maganto-Garcia E; Stavrakis G; Tajima G; Lederer J; Jarolim P; Freeman GJ; Sharpe AH; Lichtman AH Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1100-7. PubMed ID: 21393583 [TBL] [Abstract][Full Text] [Related]
17. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes. Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786 [TBL] [Abstract][Full Text] [Related]
18. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874 [TBL] [Abstract][Full Text] [Related]
19. Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. Martin-Orozco N; Wang YH; Yagita H; Dong C J Immunol; 2006 Dec; 177(12):8291-5. PubMed ID: 17142723 [TBL] [Abstract][Full Text] [Related]
20. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]